GSK venture group backs SpringLeaf's home administration for biologics
This article was originally published in Scrip
Executive Summary
The Boston-based company, SpringLeaf Therapeutics, has come out of stealth mode and reported that it has closed a $15 million Series B round of venture capital to help bring its first drug-device combo for self administration into the clinic, with GlaxoSmithKline's corporate venturing unit, SR One, leading the round.